Hookipa Pharma Stock Performance
| HOOK Stock | USD 1.76 0.02 1.12% |
The company retains a Market Volatility (i.e., Beta) of -0.26, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Hookipa Pharma are expected to decrease at a much lower rate. During the bear market, Hookipa Pharma is likely to outperform the market. At this point, Hookipa Pharma has a negative expected return of -0.5%. Please make sure to check out Hookipa Pharma's skewness, as well as the relationship between the day median price and relative strength index , to decide if Hookipa Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Hookipa Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in March 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
Last Split Factor 1:10 | Last Split Date 2024-07-10 |
1 | Acquisition by Oneill Julie of 9600 shares of Hookipa Pharma at 16.61 subject to Rule 16b-3 | 11/25/2024 |
2 | Acquisition by Matushansky Igor of 8079 shares of Hookipa Pharma at 0.1 subject to Rule 16b-3 | 12/06/2024 |
3 | HOOKIPA Pharma Inc. Rule 2.9 Announcement Amendment | 01/06/2025 |
4 | HOOKIPA Pharma in talks to acquire Poolbeg Pharma | 01/07/2025 |
5 | HOOKIPA Pharma explores acquisition of Poolbeg Pharma | 01/10/2025 |
6 | Poolbeg Agrees to Bid Deadline Extension for Possible Hookipa Pharma Deal - MarketWatch | 01/30/2025 |
7 | Hookipa Pharma announces enrollment completion of Phase 1b HB-500 trial - Yahoo Finance | 01/31/2025 |
8 | EcoR1 Capital, LLC Reduces Stake in HOOKIPA Pharma Inc Analyzing the Implications | 02/14/2025 |
9 | Acquisition by Oneill Julie of 20000 shares of Hookipa Pharma subject to Rule 16b-3 | 02/18/2025 |
10 | Acquisition by Peters Malte of 52000 shares of Hookipa Pharma at 1.01 subject to Rule 16b-3 | 02/26/2025 |
| Begin Period Cash Flow | 113.4 M |
Hookipa |
Hookipa Pharma Relative Risk vs. Return Landscape
If you would invest 252.00 in Hookipa Pharma on November 28, 2024 and sell it today you would lose (76.00) from holding Hookipa Pharma or give up 30.16% of portfolio value over 90 days. Hookipa Pharma is currently does not generate positive expected returns and assumes 4.813% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than Hookipa, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Hookipa Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Hookipa Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Hookipa Pharma, and traders can use it to determine the average amount a Hookipa Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1044
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | HOOK |
Estimated Market Risk
| 4.81 actual daily | 42 58% of assets are more volatile |
Expected Return
| -0.5 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Hookipa Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Hookipa Pharma by adding Hookipa Pharma to a well-diversified portfolio.
Hookipa Pharma Fundamentals Growth
Hookipa Stock prices reflect investors' perceptions of the future prospects and financial health of Hookipa Pharma, and Hookipa Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Hookipa Stock performance.
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (0.87) % | ||||
| Operating Margin | (3.74) % | ||||
| Current Valuation | (35.59 M) | ||||
| Shares Outstanding | 9.66 M | ||||
| Price To Earning | 12.06 X | ||||
| Price To Book | 0.30 X | ||||
| Price To Sales | 0.39 X | ||||
| Revenue | 20.13 M | ||||
| Gross Profit | (25.3 M) | ||||
| EBITDA | (77.34 M) | ||||
| Net Income | (81.58 M) | ||||
| Cash And Equivalents | 117.92 M | ||||
| Cash Per Share | 2.16 X | ||||
| Total Debt | 6.56 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 5.48 X | ||||
| Book Value Per Share | 5.96 X | ||||
| Cash Flow From Operations | (57.52 M) | ||||
| Earnings Per Share | (3.67) X | ||||
| Market Capitalization | 19.65 M | ||||
| Total Asset | 161.34 M | ||||
| Retained Earnings | (369.26 M) | ||||
| Working Capital | 105.13 M | ||||
| Current Asset | 26.61 M | ||||
| Current Liabilities | 25.01 M | ||||
About Hookipa Pharma Performance
By examining Hookipa Pharma's fundamental ratios, stakeholders can obtain critical insights into Hookipa Pharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Hookipa Pharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (48.83) | (51.27) | |
| Return On Tangible Assets | (0.58) | (0.61) | |
| Return On Capital Employed | (0.94) | (0.99) | |
| Return On Assets | (0.58) | (0.61) | |
| Return On Equity | (1.04) | (0.99) |
Things to note about Hookipa Pharma performance evaluation
Checking the ongoing alerts about Hookipa Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Hookipa Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Hookipa Pharma generated a negative expected return over the last 90 days | |
| Hookipa Pharma may become a speculative penny stock | |
| Hookipa Pharma has high historical volatility and very poor performance | |
| Hookipa Pharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 20.13 M. Net Loss for the year was (81.58 M) with loss before overhead, payroll, taxes, and interest of (25.3 M). | |
| Hookipa Pharma currently holds about 117.92 M in cash with (57.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.16, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 59.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: EcoR1 Capital, LLC Reduces Stake in HOOKIPA Pharma Inc Analyzing the Implications |
- Analyzing Hookipa Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Hookipa Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Hookipa Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Hookipa Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Hookipa Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Hookipa Pharma's stock. These opinions can provide insight into Hookipa Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hookipa Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hookipa Pharma. If investors know Hookipa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hookipa Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.67) | Revenue Per Share | Quarterly Revenue Growth (0.32) | Return On Assets | Return On Equity |
The market value of Hookipa Pharma is measured differently than its book value, which is the value of Hookipa that is recorded on the company's balance sheet. Investors also form their own opinion of Hookipa Pharma's value that differs from its market value or its book value, called intrinsic value, which is Hookipa Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hookipa Pharma's market value can be influenced by many factors that don't directly affect Hookipa Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hookipa Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hookipa Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.